Randomized trial · people

Tirzepatide: up to 20.9% weight loss at 72 weeks in SURMOUNT-1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large 72-week trial of adults with obesity, tirzepatide led to far more weight loss than placebo at all three doses tested, and gut side effects were the most common problem, mainly during the dose step-up.

Kind
Randomized trial
Studied in
People
Number studied
2539
Published
2022
Journal
N Engl J Med

What they tested

The team tested how much weight adults with obesity but without diabetes lose on weekly tirzepatide shots compared with placebo, and how safe the drug is for them.

How the study was done

A phase 3, double-blind, randomized, placebo-controlled trial split 2539 adults without diabetes into four equal groups. All had a BMI (weight relative to height) of 30 or more, or of 27 or more with at least one weight-related health problem. Three groups injected tirzepatide under the skin once a week, one group per dose level (5 mg, 10 mg and 15 mg), and the fourth group got a dummy shot (placebo). Treatment lasted 72 weeks, and doses were raised step by step over the first 20 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 72, average body weight fell by 15.0% in the 5 mg arm, 19.5% in the 10 mg arm and 20.9% in the 15 mg arm, compared with 3.1% on placebo. A weight loss of at least 5% was reached by 85%, 89% and 91% of people on the three doses, against 35% on placebo, and 50% of the 10 mg arm and 57% of the 15 mg arm lost 20% or more, against 3% on placebo. All of the planned heart and metabolic measures got better on tirzepatide. Stomach and gut side effects were the most common, were mostly mild to moderate and came mainly during the dose step-up, and side effects led 4.3%, 7.1% and 6.2% of people on the three doses to stop treatment, against 2.6% on placebo.

What it doesn’t show

People with diabetes were excluded, and the trial ran for 72 weeks, so it does not show longer-term results or results in people with diabetes. The study was funded by Eli Lilly.

The paper

Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo